{
    "gtbl": [
        "The stock has given close to 2200% returns in the last five years.",
        "The company's revenues have been growing at an extremely high rate, with margins and earnings per share also increasing significantly.",
        "The stock's PE is currently at 19, compared to the Nifty Pharma PE of 31.",
        "The PEG ratio of the stock is currently 0.27, indicating it is undervalued.",
        "The company has the potential to grow from a small cap to a mid or large cap stock."
    ],
    "username": "Rahul Jain"
}